 This pilot study suggests that patients with atopic dermatitis have increased expression of CD23 on B lymphocytes and on their subsets, as well as higher expression of CD200 on switched B lymphocytes when treated with dupilumab. This article was authored by Jamila Elikovska, Eva Omakova, Petra Boudkova, and others.